Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Cellectis S.A.
  6. News
  7. Summary
    ALCLS   FR0010425595

CELLECTIS S.A.

(ALCLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Rise Nearly 1% Friday Morning

08/27/2021 | 11:19am EDT


© MT Newswires 2021
All news about CELLECTIS S.A.
11:10aEuropean ADRs Move Higher in Friday Trading
MT
10/21European ADRs Move Lower in Thursday Trading
MT
10/19CELLECTIS S A : Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients..
PU
10/19CELLECTIS S A : Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients..
PU
10/19Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients wi..
CI
10/19CELLECTIS : Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients wit..
AQ
10/19European ADRs 0.6% Higher Tuesday Morning
MT
10/14European ADRs Climb Higher in Thursday Trading
MT
10/13European ADRs Move Higher in Wednesday Trading
MT
10/13Health Care Stocks Mixed Premarket Wednesday
MT
More news
Analyst Recommendations on CELLECTIS S.A.
More recommendations
Financials
Sales 2021 60,9 M 70,9 M 70,9 M
Net income 2021 -109 M -127 M -127 M
Net cash 2021 76,2 M 88,8 M 88,8 M
P/E ratio 2021 -3,14x
Yield 2021 -
Capitalization 423 M 492 M 493 M
EV / Sales 2021 5,69x
EV / Sales 2022 5,50x
Nbr of Employees 277
Free-Float 84,4%
Chart CELLECTIS S.A.
Duration : Period :
Cellectis S.A. Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 9,30 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
André Choulika Chief Executive Officer & Director
Eric Dutang Chief Financial Officer
Jean-Pierre Garnier Non-Executive Chairman
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
CELLECTIS S.A.-61.89%513
MODERNA, INC.212.57%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-2.12%31 638
CELLTRION, INC.-38.86%25 233